Journal of Oncology / 2014 / Article / Tab 4

Clinical Study

Survival Advantage Associated with Decrease in Stage at Detection from Stage IIIC to Stage IIIA Epithelial Ovarian Cancer

Table 4

Treatment outcomes Stage IIIA versus Stage IIIC epithelial ovarian cancer, University of Kentucky Markey Cancer Center 2000–2009.

IIIAIIICSignificance
()()

Complete debulking (no visible residual disease)15 (100%)64 (34.4%)
Complete response to chemotherapy15 (100%)138 (74.2%)
Time to progression
 Median (months)2913
 Mean (months)*
 Range (months)15–752–123
Site of recurrence
 Intraperitoneal7 (46.7%)137 (73.7%)
 Intra- + extraperitoneal08 (4.3%)
 Extraperitoneal014 (7.5%)
 NED**8 (53.3%)27 (14.5%)
Overall survival
 2 years93.3%72.0%
 5 years60.0%41.8%

Mean ± standard error of mean.
NED: no evidence of disease.